D. E. Shaw & Co., Inc. Viking Therapeutics, Inc. Call Options Transaction History
D. E. Shaw & Co., Inc.
- $107 Billion
- Q3 2024
Call Options
2 transactions
Others Institutions Holding VKTX
# of Institutions
473Shares Held
66.2MCall Options Held
5.72MPut Options Held
3.39M-
Vanguard Group Inc Valley Forge, PA10.2MShares$535 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$317 Million0.01% of portfolio
-
State Street Corp Boston, MA4.67MShares$246 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.12MShares$111 Million0.01% of portfolio
-
Morgan Stanley New York, NY1.87MShares$98.6 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $4.03B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...